Chondrosarcoma
What's New
Last Posted: Oct 04, 2023
- IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.
Elisabetta Setola, et al. BMC cancer 2023 0 (1) 907 - Clinico-genomic profiling of conventional and dedifferentiated chondrosarcomas reveals TP53 mutation to be associated with worse outcomes.
Ryan A Denu, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 0 - Isocitrate Dehydrogenase 1 and 2 Mutations in Pediatric Neuroblastoma Patients.
Emre Leventoglu, et al. Medeniyet medical journal 2023 0 (2) 102-110 - Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma.
Dermawan Josephine Kam Tai, et al. Cancer research communications 2023 0 (3) 431-443 - Characterisation of isocitrate dehydrogenase 1/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma.
Mohammad Nissreen, et al. Histopathology 2019 0 (5) 722-730 - Functional testing of thousands of osteoarthritis-associated variants for regulatory activity.
Klein Jason C, et al. Nature communications 2019 0 (1) 2434 - Genomic Profiling of Low-grade Intramedullary Cartilage Tumors Can Distinguish Enchondroma From Chondrosarcoma.
Joseph Nancy M, et al. The American journal of surgical pathology 2020 0 (6) 812-819 - Association of TP53 Alteration with Tissue Specificity and Patient Outcome of IDH1-Mutant Glioma.
Murnyak Balazs, et al. Cells 2021 0 (8) - Fresh Tissue Multi-omics Profiling Reveals Immune Classification and Suggests Immunotherapy Candidates for Conventional Chondrosarcoma.
Li Binghao, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 0 (23) 6543-6558 - Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes.
Pathmanapan Sinthu, et al. Cancer & metabolism 2021 0 (1) 13 - A genetic model for central chondrosarcoma evolution correlates with patient outcome.
Cross William, et al. Genome medicine 2022 0 (1) 99 - Periosteal chondrosarcoma: A case series in a referral center with survivorship analysis.
Pacheco Marina, et al. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2022 0 (8) 1730-1738 - Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis.
Saikiran Reddy M, et al. Cellular signalling 2022 0 110279 - Deep learning models for predicting the survival of patients with chondrosarcoma based on a surveillance, epidemiology, and end results analysis.
Yan Lizhao et al. Frontiers in oncology 2022 12967758 - Prognostic impact of IDH mutations in chondrosarcoma.
Nakagawa Makoto, et al. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 2021 9 - Targeted Next-Generation Sequencing Identifies Molecular and Genetic Events in Dedifferentiated Chondrosarcoma.
Lucas Calixto-Hope G et al. Archives of pathology & laboratory medicine 2020 Nov - Insulin-Like Growth Factor 1 (IGF1) Pathway Member Polymorphisms Are Associated with Risk and Prognosis of Chondrosarcoma.
Xie Hui, et al. Medical science monitor : international medical journal of experimental and clinical research 2020 4 e923853 - ZNF687 Mutations in an Extended Cohort of Neoplastic Transformations in Paget's Disease of Bone: Implications for Clinical Pathology.
Scotto di Carlo Federica, et al. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2020 2 - Novel prognostication of patients with spinal and pelvic chondrosarcoma using deep survival neural networks.
Ryu Sung Mo et al. BMC medical informatics and decision making 2020 Jan 20(1) 3 - Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma.
Zhu Guo Gord, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2019 10
More
About Rare Diseases PHGKB
Rare Disease PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other information that address the public health impact and translation of genomic and other precision health discoveries into improved health outcomes related to rare diseases...more
Content Summary
Selected Rare Diseases
- Alpha-1 Antitrypsin Deficiency
- Amyotrophic Lateral Sclerosis
- Brugada Syndrome
- Cerebral Palsy
- Cystic Fibrosis
- Duchenne Muscular Dystrophy
- Eclampsia
- Erythema Multiforme
- Familial Mediterranean Fever
- Fragile X Syndrome
- Gaucher Disease
- Glomerulonephritis
- Graves Disease
- Hemophilia
- Huntington Disease
- Microcephaly
- Myasthenia Gravis
- Phenylketonuria
- Retinitis Pigmentosa
- Severe Combined Immunodeficiency
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 25, 2024
- Content source: